Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pretomanid

FDA-approved product (tablet, oral), marketed as Pretomanid.

Registered studies
49
Lab records
57
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Pretomanid
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Drug-resistant tuberculosis
  • Multidrug-resistant tuberculosis
  • Pulmonary tuberculosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other drugs for treatment of tuberculosis
FDA pharmacologic class
Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AK08; FDA class Antimycobacterial

Repurposing investigation

Pretomanid is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli34.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis98.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

  • M. tuberculosis: measured active in 52 of 57 lab records
Open Pretomanid in ChEMBL Registered studies below
Show the 57 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pretomanid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Pan-TB Regimen Targeting Host and Microbe

    NCT05686356 · start 2023-07-28

    Registered record
    Registry ID
    NCT05686356
    Conditions
    Tuberculosis
    Interventions
    Sutezolid; N-acetyl cysteine; Pretomanid; Bedaquiline; Rifafour
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2023-07-28
    Completion
    2026-01
    Enrolment
    352

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionSutezolid; N-acetyl cysteine; Pretomanid; Bedaquiline +1 more
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis

    NCT05971602 · start 2023-07-26

    Registered record
    Registry ID
    NCT05971602
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS); Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS); Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE); Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS); Isoniazid and Rifampicin (HR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2023-07-26
    Completion
    2025-02-06
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionDelamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS); Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS); Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE); Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS) +1 more
    PhasePhase 2
    Registry statusTerminated

  • Safety and Efficacy Evaluation of <Dovprela Tablets 200 mg> by Post-marketing Surveillance

    NCT06471088 · start 2023-07-23

    Registered record
    Registry ID
    NCT06471088
    Conditions
    Dovprela
    Interventions
    Dovprela
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-07-23
    Completion
    2026-06-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDovprela
    InterventionDovprela
    PhaseNot recorded
    Registry statusUnknown

  • Biodistribution and Pharmacokinetics of Pretomanid in Tuberculosis Patients Using 18F-Pretomanid PET

    NCT05609552 · start 2023-05-22

    Registered record
    Registry ID
    NCT05609552
    Conditions
    Tuberculosis
    Interventions
    18F-Pretomanid PET/CT
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-05-22
    Completion
    2025-10-28
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Intervention18F-Pretomanid PET/CT
    PhaseNot recorded
    Registry statusCompleted

  • PanACEA - STEP2C -01

    NCT05807399 · start 2023-04-14

    Registered record
    Registry ID
    NCT05807399
    Conditions
    Pulmonary Tuberculosis; Other Specified Pulmonary Tuberculosis
    Interventions
    BTZ-043; Rifampicin; Isoniazid; Pyrazinamide; Moxifloxacin; Alpibectir (GSK3729098); Ganfeborole (GSK3036656); Delpazolid (LCB01-0371); Pretomanid (Pa); Ethambutol (E); Ethionamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-04-14
    Completion
    2027-12-30
    Enrolment
    390

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis; Other Specified Pulmonary Tuberculosis
    InterventionBTZ-043; Rifampicin; Isoniazid; Pyrazinamide +7 more
    PhasePhase 2
    Registry statusRecruiting

  • BPaL(M) Regimen for the Treatment of MDR/RR-TB

    NCT05381194 · start 2022-12-13

    Registered record
    Registry ID
    NCT05381194
    Conditions
    Multidrug- and Rifampicin-resistant Tuberculosis
    Interventions
    BPaL(M) regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-12-13
    Completion
    2027-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultidrug- and Rifampicin-resistant Tuberculosis
    InterventionBPaL(M) regimen
    PhasePhase 4
    Registry statusRecruiting

  • Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis

    NCT05382312 · start 2022-07-26

    Registered record
    Registry ID
    NCT05382312
    Conditions
    Tuberculosis
    Interventions
    GSK3036656; Bedaquiline; Delamanid; RIFAFOUR e-275; BTZ-043; Pretomanid; Linezolid; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-07-26
    Completion
    2025-05-27
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionGSK3036656; Bedaquiline; Delamanid; RIFAFOUR e-275 +4 more
    PhasePhase 2
    Registry statusCompleted

  • Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India

    NCT05040126 · start 2021-10-07

    Registered record
    Registry ID
    NCT05040126
    Conditions
    Pre-Extensively Drug-Resistant Pulmonary TB; Treatment Intolerant Multidrug-Resistant Pulmonary TB; Non-responsive Multidrug-Resistant Pulmonary TB
    Interventions
    Linezolid; Bedaquiline; Pretomanid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-10-07
    Completion
    2024-12-31
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPre-Extensively Drug-Resistant Pulmonary TB; Treatment Intolerant Multidrug-Resistant Pulmonary TB; Non-responsive Multidrug-Resistant Pulmonary TB
    InterventionLinezolid; Bedaquiline; Pretomanid
    PhasePhase 3
    Registry statusUnknown

  • A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis

    NCT04179500 · start 2021-09-16

    Registered record
    Registry ID
    NCT04179500
    Conditions
    Tuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR; Tuberculosis; Drug-Resistant Tuberculosis
    Interventions
    Pretomanid; Bedaquiline; moxifloxacin; pyrazinamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-09-16
    Completion
    2024-07-17
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR; Tuberculosis +1 more
    InterventionPretomanid; Bedaquiline; moxifloxacin; pyrazinamide
    PhasePhase 2
    Registry statusCompleted

  • Economic Evaluation of New MDR TB Regimens

    NCT04207112 · start 2020-10-20

    Registered record
    Registry ID
    NCT04207112
    Conditions
    Multi-drug Resistant Tuberculosis; Extensively Drug-Resistant Tuberculosis; Pulmonary Tuberculoses
    Interventions
    Bedaquiline; Pretomanid; Moxifloxacin; Linezolid; Clofazimine; Standard Drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-10-20
    Completion
    2022-08-25
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-drug Resistant Tuberculosis; Extensively Drug-Resistant Tuberculosis; Pulmonary Tuberculoses
    InterventionBedaquiline; Pretomanid; Moxifloxacin; Linezolid +2 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid

    NCT04309656 · start 2020-01-14

    Registered record
    Registry ID
    NCT04309656
    Conditions
    Multi-drug Resistant Tuberculosis
    Interventions
    Pretomanid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-14
    Completion
    2020-02-28
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-drug Resistant Tuberculosis
    InterventionPretomanid
    PhasePhase 1
    Registry statusCompleted

  • Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial

    NCT03942354 · start 2019-09-01

    Registered record
    Registry ID
    NCT03942354
    Conditions
    Multidrug Resistant Tuberculosis
    Interventions
    Bedaquiline; Pretomanid; Moxifloxacin; Linezolid; Clofazimine; Directly observed therapy (DOT)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-09-01
    Completion
    2022-05-10
    Enrolment
    137

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultidrug Resistant Tuberculosis
    InterventionBedaquiline; Pretomanid; Moxifloxacin; Linezolid +2 more
    PhaseNot recorded
    Registry statusCompleted

  • PRACTECAL-PKPD Sub Study

    NCT04081077 · start 2019-08-06

    Registered record
    Registry ID
    NCT04081077
    Conditions
    Multi-drug Resistant Tuberculosis; Extensively Drug-Resistant Tuberculosis; Pulmonary Tuberculosis
    Interventions
    Bedaquiline; Pretomanid; Moxifloxacin; Linezolid; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2019-08-06
    Completion
    2022-09-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-drug Resistant Tuberculosis; Extensively Drug-Resistant Tuberculosis; Pulmonary Tuberculosis
    InterventionBedaquiline; Pretomanid; Moxifloxacin; Linezolid +1 more
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients

    NCT03338621 · start 2018-07-30

    Registered record
    Registry ID
    NCT03338621
    Conditions
    Tuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR; Tuberculosis; Drug-Resistant Tuberculosis
    Interventions
    Pretomanid; Bedaquiline; Moxifloxacin; Pyrazinamide; HRZE; HR
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2018-07-30
    Completion
    2022-06-10
    Enrolment
    455

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR; Tuberculosis +1 more
    InterventionPretomanid; Bedaquiline; Moxifloxacin; Pyrazinamide +2 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Pretomanid in Adults With Hepatic Impairment

    NCT02422524 · start 2018-03-29

    Registered record
    Registry ID
    NCT02422524
    Conditions
    Tuberculosis
    Interventions
    PA-824
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2018-03-29
    Completion
    2023-11-17
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionPA-824
    PhasePhase 1
    Registry statusTerminated